NASDAQ:CRIS Curis (CRIS) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CRIS Stock Alerts $14.52 -0.25 (-1.69%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$14.07▼$14.8250-Day Range$9.51▼$16.8052-Week Range$3.80▼$19.60Volume10,246 shsAverage Volume35,121 shsMarket Capitalization$85.52 millionP/E RatioN/ADividend YieldN/APrice Target$37.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Curis alerts: Email Address Curis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside155.7% Upside$37.33 Price TargetShort InterestHealthy1.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.92) to ($4.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 starsMedical Sector607th out of 907 stocksBiological Products, Except Diagnostic Industry105th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingCuris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCuris has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.01% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently increased by 18.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRIS. Previous Next 2.3 News and Social Media Coverage News SentimentCuris has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Curis this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CRIS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows2 people have added Curis to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.81% of the stock of Curis is held by insiders.Percentage Held by InstitutionsOnly 29.97% of the stock of Curis is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Curis are expected to grow in the coming year, from ($5.92) to ($4.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCuris has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Curis Stock (NASDAQ:CRIS)Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Read More CRIS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRIS Stock News HeadlinesApril 25, 2024 | americanbankingnews.comCuris (NASDAQ:CRIS) Shares Cross Above Two Hundred Day Moving Average of $10.29April 23, 2024 | finance.yahoo.comCuris, Inc. (CRIS)April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 18, 2024 | finance.yahoo.comCuris, Inc. (CRIS) Interactive Stock Chart - Yahoo FinanceApril 17, 2024 | americanbankingnews.comCuris (NASDAQ:CRIS) Share Price Crosses Above 200-Day Moving Average of $10.73April 5, 2024 | prnewswire.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 4, 2024 | prnewswire.comCuris to Present at Upcoming Healthcare Conferences in AprilApril 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 28, 2024 | finance.yahoo.comCuris, Inc. (CRIS) Stock Historical Prices & Data - Yahoo FinanceFebruary 24, 2024 | benzinga.comCuris Stock (NASDAQ:CRIS) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comCuris Stock (NASDAQ:CRIS), Analyst Ratings, Price Targets, PredictionsFebruary 10, 2024 | msn.comCuris Inc. Is Worried About This – Should You Be Worried Too?February 9, 2024 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call TranscriptFebruary 8, 2024 | finanznachrichten.deCuris, Inc.: Curis Provides Fourth Quarter 2023 Business UpdateFebruary 8, 2024 | markets.businessinsider.comCuris Inc Q4 sales declineFebruary 8, 2024 | finance.yahoo.comCuris Provides Fourth Quarter 2023 Business UpdateFebruary 7, 2024 | benzinga.comCuris's Earnings: A PreviewFebruary 1, 2024 | finance.yahoo.comCuris to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024January 22, 2024 | finance.yahoo.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 18, 2023 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For ExcitementDecember 12, 2023 | markets.businessinsider.comBuy Rating on Curis Backed by Promising Clinical Trials and Strategic ExpansionDecember 12, 2023 | finance.yahoo.comCuris Announces Initial Combination Study Data from its TakeAim Lymphoma StudyDecember 11, 2023 | finance.yahoo.comCuris Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH ConferenceDecember 6, 2023 | markets.businessinsider.comPositive Buy Rating for Curis Stock Driven by Emavusertib’s Clinical Promise and Revenue PotentialDecember 6, 2023 | finance.yahoo.comCuris Announces Three Presentations at ASHDecember 5, 2023 | markets.businessinsider.comCuris Inks Deal With Florida University For Emavusertib/Pembrolizumab Combination Study In MelanomaSee More Headlines Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today4/25/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:CRIS CUSIP23126910 CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees49Year Founded2000Price Target and Rating Average Stock Price Target$37.33 High Stock Price Target$60.00 Low Stock Price Target$26.00 Potential Upside/Downside+155.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($8.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,410,000.00 Net Margins-473.04% Pretax Margin-473.04% Return on Equity-169.22% Return on Assets-54.79% Debt Debt-to-Equity RatioN/A Current Ratio4.51 Quick Ratio4.51 Sales & Book Value Annual Sales$10.02 million Price / Sales8.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book4.37Miscellaneous Outstanding Shares5,890,000Free Float5,610,000Market Cap$85.99 million OptionableNo Data Beta3.72 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. James E. Dentzer (Age 57)President, CEO, Secretary, Treasurer & Director Comp: $912.29kMs. Diantha Duvall CPA (Age 52)M.B.A., CFO and Principal Financial & Accounting Officer Comp: $588.95kMr. Mark W. Noel (Age 65)Vice President of Technology Management & Intellectual Property Comp: $279.28kMs. Elif McDonaldVP of Investor Relations & Corporate CommunicationsDr. Reinhard Wilhelm von Roemeling M.D.Senior Vice President of Clinical DevelopmentDr. Jonathan B. Zung Ph.D. (Age 59)Chief Development Officer More ExecutivesKey CompetitorsNeon TherapeuticsNASDAQ:NTGNSangamo TherapeuticsNASDAQ:SGMOAgenusNASDAQ:AGENSAB BiotherapeuticsNASDAQ:SABSProtalix BioTherapeuticsNYSE:PLXView All CompetitorsInstitutional OwnershipFranklin Street Advisors Inc. NCBought 20,128 shares on 4/16/2024Ownership: 0.342%Kingdon Capital Management L.L.C.Sold 25,000 shares on 3/18/2024Ownership: 4.824%a16z Perennial Management L.P.Bought 6,653 shares on 2/6/2024Ownership: 0.113%Arnhold LLCSold 1,302 shares on 2/5/2024Ownership: 0.277%View All Institutional Transactions CRIS Stock Analysis - Frequently Asked Questions Should I buy or sell Curis stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRIS shares. View CRIS analyst ratings or view top-rated stocks. What is Curis' stock price target for 2024? 3 brokers have issued 12 month target prices for Curis' stock. Their CRIS share price targets range from $26.00 to $60.00. On average, they anticipate the company's share price to reach $37.33 in the next twelve months. This suggests a possible upside of 155.7% from the stock's current price. View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts. How have CRIS shares performed in 2024? Curis' stock was trading at $12.75 at the start of the year. Since then, CRIS shares have increased by 14.5% and is now trading at $14.60. View the best growth stocks for 2024 here. Are investors shorting Curis? Curis saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 59,400 shares, an increase of 18.6% from the March 31st total of 50,100 shares. Based on an average trading volume of 35,000 shares, the days-to-cover ratio is presently 1.7 days. Approximately 1.0% of the company's shares are sold short. View Curis' Short Interest. When is Curis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CRIS earnings forecast. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings data on Thursday, February, 8th. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.91) by $0.12. The biotechnology company earned $2.70 million during the quarter, compared to analyst estimates of $2.95 million. Curis had a negative trailing twelve-month return on equity of 169.22% and a negative net margin of 473.04%. During the same quarter in the previous year, the firm posted ($2.40) EPS. When did Curis' stock split? Curis shares reverse split on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK). Who are Curis' major shareholders? Curis' stock is owned by a number of institutional and retail investors. Top institutional investors include Franklin Street Advisors Inc. NC (0.34%). View institutional ownership trends. How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRIS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
